Last updated on February 2018

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients


Brief description of study

Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma

Clinical Study Identifier: NCT02945215

Contact Investigators or Research Sites near you

Start Over

Huaqing Wang

Tianjin People's Hospital
Tianjin, China
  Connect »